US Edition
Published • loading... • Updated
Amgen Reports Positive Phase 3 Data for Subcutaneous Tepezza in Thyroid Eye Disease
Summary by Patient Worthy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Amgen Reports Positive Phase 3 Data for Subcutaneous Tepezza in Thyroid Eye Disease
As reported on PharmaBiz, Amgen has announced encouraging topline results from a phase 3 clinical trial evaluating a subcutaneous formulation of Tepezza (teprotumumab-trbw) for adults with moderate-to-severe active thyroid eye disease (TED). The study showed that administration via an on‑body injector (OBI) achieved efficacy comparable to the established intravenous (IV) formulation, offering a potentially more […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
